NanoForm’s mission is to bring new generations of drugs to the market. The company is engaged in the development of proprietary NanoActive formulations of several blockbuster drugs.
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist which is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. The unformulated compound shows marked positive food effect which was practically eliminated using the NanoActive formulation.
Sildenafil Citrate is used to treat erectile dysfunction and pulmonary arterial hypertension. The compound was initially developed for use in hypertension and angina pectoris. When taken orally after a high fat meal there is a delay in the absorption of Sildenafil Citrate. The NanoActive version not only has improved pH independent solubility and dissolution profile, but also has eliminated food effect.
Telmisartan is an angiotensin II receptor antagonist, which is widely used in the treatment of hypertension. NanoActive Telmisartan was developed with DRGT’s proprietary continuous flow NanoActive technology. The NanoActive formulation has increased pH independent solubility and dissolution profile which resulted in greater bioavailability and improved PK profile.
Candesartan Cilexetil selectively blocks the binding of angiotensin II to the AT1 receptor, resulting in a decrease in blood pressure. Based on the results of solubility, PAMPA permeability and in vivo oral absorption studies increased solubility and dissolution characteristics of the NanoActive Candesartan Cilexetil results in increased oral absorption and bioavailability.
Olmesartan Medoxomil is a specific angiotensin II type 1 antagonist and acts as an antihypertensive agent, lowering blood pressure. The NanoActive formulation of Olmesartan shows increased oral absorption and bioavailability.